Table 5.
Summary of studies reporting prognostic factors in anaplastic oligodendrogliomas within the 10 last years.
| Author, year | Study population | Number of patients | 1p/19q codeletion (n = %) | Analysis restricted to 1p/19q codeleted AO | Characteristics associated with worse prognosis | (Refs.) | ||
|---|---|---|---|---|---|---|---|---|
| Clinico-radiological | Histo-molecular | Treatment related | ||||||
| Roux, 2020 | O, AO | 108 | 108 (100) | No | Growth rate ≥8 mm/year | 16 | ||
| Garton, 2020 | O, AO | 2514 | 1067 (42) | No | Older age, worse comorbidity index, infratentorial location | Grade III | No debulking, RT | 17 |
| Shin, 2020 | AO | 95 | 31 (32) | No | Ki67 (>20%), no IDH mutation | 18 | ||
| Lin, 2020 | O, AO | 186 | 186 (100) | No | Older age, lower KPS | 19 | ||
| Pouget, 2020 | AO | 220 | 220 (100) | Yes | Older age | MCM6 ≥ 50% or Ki67 ≥ 15% |
20 | |
| Appay, 2019 | AO, AA, GBM IDHm | 911 | 483 (53) | Yes | Older age | CDKN2A deletion | 21 | |
| Kinslow, 2019 | O, AO | 3135 | unknown | No | Year of diagnosis, older age, sex (male), single status, infratentorial location | Grade III | No debulking, RT | 22 |
| Chen, 2019 | O, AO | 412 | 333 (80) | No | Older age, grade III | No 1p19q codeletion, 1p19q codeletion with polysomy |
No GTR | 23 |
| Liu, 2019 | AO | 1899 | Unknown | No | Older age, single status, multiple primary malignancies | No surgery | 9 | |
| Yeboa, 2018 | O, AO | 1618 | 1618 (100) | No | Older age, worse comorbidity index, lower income | Astrocytoma/mixed glioma, grade III | 24 | |
| Halani, 2018 | O, AO | 169 | 169 (100) | No | Older age | Grade III, PI3K mutations | 25 | |
| Appay, 2018 | AO | 227 | 227 (100) | Yes | Older age | Necrosis, higher proliferative index, absence of SSTR2A expression | 26 | |
| Rosenberg, 2018 | AO | 197 | 197 (100) | Yes | Older age | Necrosis, severe nuclear atypia, deletion of peak 9p21.3; amplification of peaks 14q13.1, 11q14.2, 20q13.33, and 1q21.3; CN‐LOH peak 17p11.2; gain of 11p | 27 | |
| Aoki, 2018 | O, AO, A, AA | 414 | 164 (39) | No | Age (≥60) | Notch1 mutation | No GTR | 28 |
| Zetterling, 2017 | O, AO | 214 | 64 (30) | No | Older age, non-frontal location, neurological deficit or personality change | No IDH-mt and no 1p/19q codel | 8 | |
| Figarella-Brnager, 2016 | AO | 157 | 157 (100) | Yes | Older age | MVP, necrosis, mitosis, KI67 LI | 29 | |
| Hu, 2017 | O, AO | 374 | 374 (100) | No | Older age | Grade III, gene expression profile | 30 | |
| Kamoun, 2016 | AO, AA, GBM IDHm | 156 | 80 (51) | No | Older age | Grade III, gene expression profile | 31 | |
| Kang, 2015 | AO | 376 | 95 (25) | Yes | Age (>45), KPS (<70), non-frontal lobe location | No complete removal, no RT | 32 | |
| Preusser, 2012 | AO | 281 | 76 (27) | No | Higher proliferative index | 33 | ||
| Lassman, 2011 | AO | 1013 | 301 (29) | No | Age (≥50), KPS (<70), non-frontal lobe location, bilateral hemispheric involvement | No 1p/19q codeletion | Biopsy, RT alone | 7 |
AO, anaplastic oligodendroglioma; A, astrocytoma; AA, anaplastic astrocytoma; CN-LOH, copy-neutral loss of heterozygosity; GBM, glioblastoma; GTR, gross total resection; KPS, Karnofsky performance status; LI, label index; MVP, microvascular proliferation; O, oligodendroglioma; RT, radiotherapy.